We were delighted to catch up with touchONCOLOGY editorial board member Professor Robin Foà (Sapienza University of Rome, Italy) to discuss his educational session at the 63rd ASH Annual Meeting & Exposition on measurable residual disease in the management of many haematological malignancies. (PART THREE)
1. What is the current role of measurable residual disease (MRD) in guiding decision making in clinical practice? 00:15-03:38
2. What are the barriers to more widespread implementation of MRD in clinical practice and how are these being overcome? 03:38-06:16
Speaker Disclosure: Robin Foà has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 63rd ASH Annual Meeting & Exposition
Share this Video
Related Videos In Haematological Malignancies
PERSEUS trial results: Daratumumab + VRd in newly diagnosed multiple myeloma: ASH 2023, Pieter Sonneveld
The randomized phase III PERSEUS trial (NCT03710603) investigated daratumumab in combination with bortezomib, lenalidomide, and dexamethasone (VRd) compared with VRd and lenalidomide alone in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM). Daratumumab, a CD38 monoclonal antibody, is currently approved for use in several treatment regimens aimed at both transplant-eligible and non-transplant-eligible NDMM. In this […]
Binod Dhakal, ASCO 2023: The CARTITUDE-4 trial, ciltacabtagene autoleucel for patients with lenalidomide-refractory multiple myeloma
Lenalidomide is a standard of care in multiple myeloma. But with the prevalence of the lenalidomide-refractory population increasing, the CARTITUDE-4 trial aimed to assess ciltacabtagene autoleucel for this patient population. In this touchONCOLOGY interview, we speak with Dr Binod Dhakal (Medical College of Wisconsin, Milwaukee, WI, USA) to discuss the mechanism of action of ciltacabtagene […]
Binod Dhakal, ASCO 2023: The treatment paradigm for multiple myeloma
The treatment paradigm for patients with multiple myeloma is very complex. In this touchONCOLOGY interview, we speak with Dr Binod Dhakal (Medical College of Wisconsin, Milwaukee, WI, USA) to break down the treatment paradigm in multiple myeloma, discussing how to handle different patient cases. The abstract entitled ‘First phase 3 results from CARTITUDE-4: Cilta-cel versus […]